Thunder Biotech, Inc. is an immune-oncology company developing patented MOTO-CAR™ technology - genetically engineered CAR macrophages - that help cancer patients' immune cells recognize and attack solid tumors.
Traditional cancer treatments— like surgery, radiation, and chemotherapy—are often ineffective, invasive, and difficult to tolerate. Thunder Biotech is designing MOTO-CAR™s to be a more effective and humane therapy.
Thunder Biotech's MOTO-CAR™s re-educate Tumor Associated Macrophages and restore their M1 ability to recognize and eliminate tumor cells. In addition, MOTO-CAR™s are armed with tumor specific receptors that directly adhere to the tumor cell surface allowing them to initiate tumor cell destruction and recruit the natural T cell response engaging them to eliminate the tumor. This T cell response will then provide the body with a memory response preventing tumor recurrence.
Company Details
- Employees
- 14
- Founded
- -
- Address
- 180 N University Avenue, Suite 820,
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- Website
- https://thunderbiotech.com
- HQ
- Provo, Utah
Thunder Biotech Questions
Thunder Biotech's website is https://thunderbiotech.com
Thunder Biotech's LinkedIn profile is https://www.linkedin.com/company/thunderbiotech
Thunder Biotech has
14 employees.
View email and phone details for 14
employees at Thunder Biotech.
Thunder Biotech's industry is
Biotechnology Research
Thunder Biotech's top competitors are
Signpath Pharma Inc.,
Peel Therapeutics,
3helix, Inc.,
Halia Therapeutics, Inc.,
Echelon Biosciences,
Biolexis Therapeutics, Inc.,
Curza,
Kinnear Pharmaceuticals,
Orizuru Therapeutics, Inc.,
Eris Biotech (Yc W24).
Thunder Biotech's categories are Biotechnology Research
Thunder Biotech's founding year is 2016
